PMI will pay Altria Group nearly $2.7 billion for exclusive U.S. commercialization rights to IQOS.Read More
Tags :IQOS
The ITC should have consulted more with the FDA prior to banning the device, say PMI lawyers. Read More
The verdict concerns counterclaims in RJR’s ongoing lawsuit over PMI’s IQOS device.Read More
Aquavape shops will now supply a range of smoking alternatives that meet market demands and trends.Read More
Because device is similar to the previous version, PMI can make the same exposure reduction claims. Read More
A design change, however, would require re-authorization from the U.S. Food and Drug Administration.Read More
The IQOS Iluma Prime launch follows the bladeless product’s initial introduction in Japan. Read More
The Biden administration lets stand a ruling that found Philip Morris' IQOS infringes on BAT patents. Read More
The U.S. trade representative will consider the FDA’s view while mulling an import ban.Read More
The agency has instituted a ban preventing IQOS from being sold in the U.S. in 60 days.Read More
